Overexpression of angiotensin II type 2 receptor suppresses neointimal hyperplasia in a rat carotid arterial balloon injury model

Molecular Medicine Reports

Volumn 4, Issue 2, 2011, Pages 249-254

  Tang, Bing ^a   Ma, Shuangtao ^a   Yang, Yongjian ^a   Yang, Dachun ^a   Chen, Jinsong ^a   Su, Xiaohua ^a   Tan, Yan ^a   Sun, Meiqin ^a   Li, De ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Angiotensin II type 2 receptor; Carotid arterial balloon injury; Neointimal hyperplasia

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; GREEN FLUORESCENT PROTEIN; KRUPPEL LIKE FACTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT ANGIOTENSIN 2 RECEPTOR; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; MALE; NEOINTIMA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; SMOOTH MUSCLE FIBER; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BALLOON DILATION; CAROTID ARTERY INJURIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HYPERPLASIA; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2; TUNICA INTIMA;

ADENOVIRIDAE; RATTUS;

EID: 79551711688     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.433     Document Type: Article

References (29)

1. Lin GA, Dudley RA and Redberg RF: Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease. Arch Intern Med 167: 1604-1609, 2007. (Pubitemid 47280340)
2. Nobuyoshi M, Kimura T, Ohishi H, et al: Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 17: 433-439, 1991.
3. Er F and Erdmann E: Drug-eluting or bare-metal stents in interventional cardiology. Theory and practice (in German). Med Klin 102: 30-32, 2007. (Pubitemid 46142563)
4. Corbett SJ, Cosgrave J, Melzi G, et al: Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur Heart J 27: 2330-2337, 2006. (Pubitemid 44453577)
5. Li D, Ma S, Li G, et al: Endovascular stent implantation for isolated pulmonary arterial stenosis caused by Takayasu's arteritis. Clin Res Cardiol 99: 573-575, 2010.
6. Shah PK: Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 107: 2175-2177, 2003.
7. Xu L, Wu Y, Feng G, et al: Endovascular irradiation prevents smooth muscle cell proliferation and neointimal hyperplasia in rabbits. J Tongji Med Univ 19: 240-245, 1999. (Pubitemid 33210474)
8. Li F, Zhang C, Schaefer S, Estes A and Malik KU: ANG II-induced neointimal growth is mediated via cPLA2- and PLD2-activated Akt in balloon-injured rat carotid artery. Am J Physiol Heart Circ Physiol 289: H2592-H2601, 2005. (Pubitemid 41698576)
9. Hutchinson HG, Hein L, Fujinaga M and Pratt RE: Modulation of vascular development and injury by angiotensin II. Cardiovasc Res 41: 689-700, 1999. (Pubitemid 29130633)
10. Van Kleef EM, Fingerle J and Daemen MJ: Angiotensin II-induced progression of neointimal thickening in the balloon-injured rat carotid artery is AT1 receptor mediated. Arterioscler Thromb Vasc Biol 16: 857-863, 1996. (Pubitemid 26234983)
11. Harada K, Komuro I, Sugaya T, Murakami K and Yazaki Y: Vascular injury causes neointimal formation in angiotensin II type 1a receptor knockout mice. Circ Res 84: 179-185, 1999. (Pubitemid 29070113)
12. Zhu J and Gao D: Losartan reduces collagen content and intimal thickening of iliac arteries after balloon injury in rabbits. J Renin Angiotensin Aldosterone Syst 1: 278-282, 2000.
13. Yamada T, Kondo T, Numaguchi Y, et al: Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells. Arterioscler Thromb Vasc Biol 27: 2363-2369, 2007. (Pubitemid 350203951)
14. Akishita M, Horiuchi M, Yamada H, et al: Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2: 13-20, 2000.
15. Henrion D, Kubis N and Levy BI: Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 38: 1150-1157, 2001. (Pubitemid 34252821)
16. Hernandez Schulman I, Zhou MS and Raij L: Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension 49: 270-271, 2007.
17. Nakajima M, Hutchinson HG, Fujinaga M, et al: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92: 10663-10667, 1995.
18. Chassagne C, Adamy C, Ratajczak P, et al: Angiotensin II AT(2) receptor inhibits smooth muscle cell migration via fibronectin cell production and binding. Am J Physiol Cell Physiol 282: C654-C664, 2002. (Pubitemid 34663128)
19. Zhang C, Zhao YX, Zhang YH, et al: Angiotensin-Converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci USA 107: 15886-15891, 2010.
20. Matsumae H, Yoshida Y, Ono K, et al: CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Arterioscler Thromb Vasc Biol 28: 1077-1083, 2008.
21. Cheng XW, Kuzuya M, Sasaki T, et al: Green tea catechins inhibit neointimal hyperplasia in a rat carotid arterial injury model by TIMP-2 overexpression. Cardiovasc Res 62: 594-602, 2004. (Pubitemid 38648974)
22. Yang DC, Ma ST, Tan Y, et al: Imbalance of matrix metalloproteinases/ tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 116: 133-141, 2010.
23. Yang D, Ma S, Li D, Tang B and Yang Y: Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem Biophys Res Commun 388: 606-611, 2009.
24. Yang D, Ma S, Tan Y, et al: Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. Int J Mol Med 26: 159-164, 2010.
25. Hannan RE and Widdop RE: Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. Curr Hypertens Rep 6: 117-123, 2004. (Pubitemid 39359551)
26. Levy BI: Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109: 8-13, 2004.
27. Gorin Y, Ricono JM, Wagner B, et al: Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 381: 231-239, 2004. (Pubitemid 38932229)
28. Stroth U, Blume A, Mielke K and Unger T: Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 78: 175-180, 2000. (Pubitemid 30417498)
29. Kawai-Kowase K, Kurabayashi M, Hoshino Y, Ohyama Y and Nagai R: Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells. Circ Res 85: 787-795, 1999. (Pubitemid 29504153)